deltatrials
Terminated PHASE1 INTERVENTIONAL 3-arm NCT04504331

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

A Phase 1B Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

Sponsor: Jennifer Lee Caswell-Jin

Conditions Breast Cancer ER Positive Breast Cancer HER2-negative Breast Cancer PR-Positive Breast Cancer
Interventions Computed tomography (CT) Infigratinib Iopamidol Omnipaque 350 Tamoxifen
Updated 12 times since 2020 Last updated: Jan 23, 2026 Started: Oct 13, 2020 Primary completion: Oct 22, 2021 Completion: Oct 22, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Drug manufacturer decision to terminate development.

Other Breast Cancer trials with similar outcome

Browse all Breast Cancer trials

Listed as NCT04504331, this PHASE1 trial focuses on Breast Cancer and ER Positive Breast Cancer and remains terminated or withdrawn. Sponsored by Jennifer Lee Caswell-Jin, it has been updated 12 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Sep 2020 – ~Nov 2020 · 2 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Mar 2022 · 9 months · monthly snapshotRecruiting~Mar 2022 – ~Nov 2022 · 8 months · monthly snapshotRecruiting~Nov 2022 – ~Jul 2023 · 8 months · monthly snapshotTerminated~Jul 2023 – ~Jul 2024 · 12 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotTerminated~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshot~Dec 2025 – ~Feb 2026 · 2 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

12 versions recorded

  1. Feb 2026 — Present [monthly]

    Terminated PHASE1

  2. Dec 2025 — Feb 2026 [monthly]

    Terminated PHASE1

  3. Sep 2025 — Dec 2025 [monthly]

    Terminated PHASE1

  4. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE1

  5. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

▶ Show 7 earlier versions

  1. Jul 2023 — Jul 2024 [monthly]

    Terminated PHASE1

  2. Nov 2022 — Jul 2023 [monthly]

    Terminated PHASE1

    Status: Recruiting → Terminated

  3. Mar 2022 — Nov 2022 [monthly]

    Recruiting PHASE1

  4. Jun 2021 — Mar 2022 [monthly]

    Recruiting PHASE1

  5. Jan 2021 — Jun 2021 [monthly]

    Recruiting PHASE1

  6. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  7. Sep 2020 — Nov 2020 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Jennifer Lee Caswell-Jin
  • National Cancer Institute (NCI)
  • QED Therapeutics, a BridgeBio company
Data source: Stanford University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations